Literature DB >> 28728889

Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers.

Eileen E Moran1, Cuiling Wang2, Mindy Katz3, Laurie Ozelius4, Alison Schwartz5, Jelena Pavlovic3, Roberto A Ortega5, Richard B Lipton3, Molly E Zimmerman6, Rachel Saunders-Pullman7.   

Abstract

Mutations in the glucocerebrosidase (GBA) gene are a strong genetic risk factor for the development of Parkinson's disease and dementia with Lewy Bodies. However the penetrance of GBA mutations is low for these diseases in heterozygous carriers. The aim of this study was to examine the relationship between mutation status and cognitive and motor functioning in a sample of community-dwelling older adults. Using linear mixed effects models, we examined the effect of heterozygous mutation status on 736 community-dwelling older adults (≥70 years) without dementia or Parkinson's disease assessed over an average of 6 years, 28 of whom had a single GBA mutation (primarily N370S). Verbal memory was measured using the picture version of the Free and Cued Selective Reminding Test, and carriers showed significantly (p < 0.05) greater decline in verbal memory over time. There was no difference in motor function or any other cognitive domain. Taken together, these results suggest an effect, but an overall limited burden, of harboring a single GBA mutation in aging mutation carriers.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Cognition; Dementia; GBA; Glucocerebrosidase; Parkinson's disease

Mesh:

Substances:

Year:  2017        PMID: 28728889      PMCID: PMC5647652          DOI: 10.1016/j.neurobiolaging.2017.06.010

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  58 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

2.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Authors:  Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

3.  Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers.

Authors:  M Anheim; A Elbaz; S Lesage; A Durr; C Condroyer; F Viallet; P Pollak; B Bonaïti; C Bonaïti-Pellié; A Brice
Journal:  Neurology       Date:  2012-01-25       Impact factor: 9.910

Review 4.  Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.

Authors:  S Pablo Sardi; Seng H Cheng; Lamya S Shihabuddin
Journal:  Prog Neurobiol       Date:  2015-01-06       Impact factor: 11.685

5.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

6.  Apolipoprotein E Genotype and Cardiovascular Diseases in the Elderly.

Authors:  Mary N Haan; Elizabeth R Mayeda
Journal:  Curr Cardiovasc Risk Rep       Date:  2010-07-16

7.  The free and cued selective reminding test: Validation for mild cognitive impairment and Alzheimer's disease.

Authors:  Raquel Lemos; Mário R Simões; Beatriz Santiago; Isabel Santana
Journal:  J Neuropsychol       Date:  2014-06-03       Impact factor: 2.864

8.  Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course.

Authors:  Núria Setó-Salvia; Javier Pagonabarraga; Henry Houlden; Berta Pascual-Sedano; Oriol Dols-Icardo; Arianna Tucci; Coro Paisán-Ruiz; Antonia Campolongo; Sofía Antón-Aguirre; Inés Martín; Laia Muñoz; Enric Bufill; Lluïsa Vilageliu; Daniel Grinberg; Mónica Cozar; Rafael Blesa; Alberto Lleó; John Hardy; Jaime Kulisevsky; Jordi Clarimón
Journal:  Mov Disord       Date:  2011-12-15       Impact factor: 10.338

9.  Survival and dementia in GBA-associated Parkinson's disease: The mutation matters.

Authors:  Roberto Cilia; Sara Tunesi; Giorgio Marotta; Emanuele Cereda; Chiara Siri; Silvana Tesei; Anna L Zecchinelli; Margherita Canesi; Claudio B Mariani; Nicoletta Meucci; Giorgio Sacilotto; Michela Zini; Michela Barichella; Corrado Magnani; Stefano Duga; Rosanna Asselta; Giulia Soldà; Agostino Seresini; Manuela Seia; Gianni Pezzoli; Stefano Goldwurm
Journal:  Ann Neurol       Date:  2016-10-03       Impact factor: 10.422

10.  Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study.

Authors:  Aya Narita; Kentarou Shirai; Shinji Itamura; Atsue Matsuda; Akiko Ishihara; Kumi Matsushita; Chisako Fukuda; Norika Kubota; Rumiko Takayama; Hideo Shigematsu; Anri Hayashi; Tomohiro Kumada; Kotaro Yuge; Yoriko Watanabe; Saori Kosugi; Hiroshi Nishida; Yukiko Kimura; Yusuke Endo; Katsumi Higaki; Eiji Nanba; Yoko Nishimura; Akiko Tamasaki; Masami Togawa; Yoshiaki Saito; Yoshihiro Maegaki; Kousaku Ohno; Yoshiyuki Suzuki
Journal:  Ann Clin Transl Neurol       Date:  2016-02-02       Impact factor: 4.511

View more
  1 in total

1.  Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers.

Authors:  Eileen E Moran; Susan B Bressman; Roberto A Ortega; Deborah Raymond; William C Nichols; Christina A Palmese; Sonya Elango; Matthew Swan; Vicki Shanker; Imali Perera; Cuiling Wang; Molly E Zimmerman; Rachel Saunders-Pullman
Journal:  Front Neurol       Date:  2021-02-26       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.